Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

TAOS1, a Novel Marker for Advanced Esophageal Squamous Cell Carcinoma

YOSHINAO KOMATSU, KENJI HIBI, YASUHIRO KODERA, SEIJI AKIYAMA, KATSUKI ITO and AKIMASA NAKAO
Anticancer Research May 2006, 26 (3A) 2029-2032;
YOSHINAO KOMATSU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI HIBI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kenjih-ngy{at}umin.ac.jp
YASUHIRO KODERA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEIJI AKIYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUKI ITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIMASA NAKAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). Materials and Methods: Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. Results: TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p=0.014) and a trend towards advanced TNM stages (p=0.074). Conclusion: The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.

  • TAOS1
  • esophageal squamous cell carcinoma
  • CCND1

Footnotes

  • Abbreviations: TAOS1, tumor amplified and overexpressed sequence 1; SCC, squamous cell carcinoma; RT-PCR, reverse transcription-PCR.

  • Received March 10, 2006.
  • Accepted April 6, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 3A
May-June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
TAOS1, a Novel Marker for Advanced Esophageal Squamous Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
TAOS1, a Novel Marker for Advanced Esophageal Squamous Cell Carcinoma
YOSHINAO KOMATSU, KENJI HIBI, YASUHIRO KODERA, SEIJI AKIYAMA, KATSUKI ITO, AKIMASA NAKAO
Anticancer Research May 2006, 26 (3A) 2029-2032;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
TAOS1, a Novel Marker for Advanced Esophageal Squamous Cell Carcinoma
YOSHINAO KOMATSU, KENJI HIBI, YASUHIRO KODERA, SEIJI AKIYAMA, KATSUKI ITO, AKIMASA NAKAO
Anticancer Research May 2006, 26 (3A) 2029-2032;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Expression of DOG1 (Using SP31) in Poorly Differentiated Carcinoma of the Head and Neck
  • Downregulation of Ca2+-Activated Cl- Channel TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing Cancer Cells
  • Viral and Molecular Aspects of Oral Cancer
  • Google Scholar

More in this TOC Section

  • Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan–Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer
  • MMP-9 Genotypes Serve as Oral Cancer Predictive Marker for Smokers
  • A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire